Targeting the mechanical phenotype displayed by aggressive dedifferentiated mesenchymal-like BRAF-mutant melanoma cells and the fibrotic-like features of melanoma tumor microenvironment in combination with current TT and ICB clearly opens promising therapeutic avenues. This evidence concerns the gene BRAF and melanoma.